INTRODUCTION
============

Bone morphogenetic proteins (BMPs) are growth factors that belong to the tumor growth factor (TGF) superfamily and have been shown to regulate multiple biological processes of development and morphogenesis ([@b6-molcell-37-3-270-12]; [@b15-molcell-37-3-270-12]; [@b19-molcell-37-3-270-12]; [@b29-molcell-37-3-270-12]). Numerous BMP ligands, type I receptors (BMPRI/ALK), and type II receptors (BMPRII) have been identified in diverse experimental model systems and in the human genome ([@b3-molcell-37-3-270-12]; [@b13-molcell-37-3-270-12]). In general, BMP ligands signal throughout hetero-tetrameric receptor complexes, which consist of two BMPRIs and two BMPRIIs. Upon activation, the BMP signaling complex undergoes Clathrin and Dab2 dependent internalization ([@b16-molcell-37-3-270-12]) and induces phosphorylation of receptor regulated SMADs (R-SMAD), such as SMAD1, 5, or 8 (9 in zebrafish), within the early endosomes ([@b14-molcell-37-3-270-12]). Once phosphorylated, R-SMADs recruit a common mediator SMAD (Co-SMAD), SMAD4, and translocate to the nucleus to promote transcription of BMP targets such as ID1 and SMAD6 ([@b13-molcell-37-3-270-12]).

During early embryogenesis, the activities of BMP signaling are important for dorso-ventral axis formation and the establishment of mesoderm-derived cell lineages ([@b19-molcell-37-3-270-12]). Lack of functional BMP signaling in embryos leads to severe dorsalization, therefore, adversely affecting specification of ventral and mesodermal cell fates ([@b19-molcell-37-3-270-12]; [@b22-molcell-37-3-270-12]; [@b29-molcell-37-3-270-12]). During organogenesis, BMP signaling regulates morphogenesis of diverse mesoderm-derived organs. For instance, a reduced level of BMP signaling causes defects in the formation of heart primordial cells and cardiac valves ([@b1-molcell-37-3-270-12]; [@b4-molcell-37-3-270-12]; [@b10-molcell-37-3-270-12]). In addition, increasing evidence suggests that BMP signaling also regulates morphogenesis of vascular networks by modulating behaviors of endothelial cells in vertebrates ([@b28-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]). In endothelial cells, BMP signaling can elicit opposite responses, depending on the type of ligand; while BMP2 and BMP6 promote angiogenesis ([@b12-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]), BMP9 and BMP10 are known to induce quiescence of endothelial cells ([@b20-molcell-37-3-270-12]; [@b25-molcell-37-3-270-12]). More recently, BMP and TGFβ signaling have been shown to regulate lymphatic endothelial cells (LECs) ([@b8-molcell-37-3-270-12]; [@b18-molcell-37-3-270-12]; [@b21-molcell-37-3-270-12]; [@b34-molcell-37-3-270-12]), which are specialized endothelial cells derived from endothelial cells within blood vessels. However, since BMP signaling can elicit drastically distinct outcomes in the same tissue dependent on the context ([@b16-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]) and there is a high degree of redundancy within the signaling pathways ([@b13-molcell-37-3-270-12]; [@b22-molcell-37-3-270-12]), it is possible that BMP signaling differently regulates LECs in a context-dependent manner. For instance, BMP ligands may bind to distinct Type I receptors (i.e. Alk2 vs Alk3), or preferentially activate distinct R-SMADs (i.e. SMAD1 vs SMAD5) to either activate or repress lymphatic development.

Therefore, we examined the function of individual BMP signaling components during lymphatic development using zebrafish as a model system. We found that many genes which function within the BMP signaling pathway, including bmpr2, bmpr1, bmpr1b, and smad5 are essential to promote lymphatic development in zebrafish. In contrast, the functions of alk2, smad1, and smad9 appear to be dispensable for early lymphatic development. Therefore, it appears that BMP signaling may promote lymphatic development *via* BMPR1/Alk3 and SMAD5 in zebrafish. Combined with our previous analyses on the role of BMP2 signaling in lymphatic development ([@b8-molcell-37-3-270-12]), our data presented here illustrate the complex and context-dependent nature of BMP signaling during lymphatic development.

MATERIALS AND METHODS
=====================

Zebrafish husbandry and microinjection
--------------------------------------

Zebrafish (*Danio rerio*) *Tg(fli1a:nEGFP)^y7^;Tg(kdrl:mCherry)^s843^* transgenic embryos and adults were raised and maintained under IACUC guidelines of Yale university. Sequences of morpholino anti-sense oligonucleotides (MO; Gene Tools, LLC) can be found in [Table 1](#t1-molcell-37-3-270-12){ref-type="table"}. MOs were injected at 1--2 cell stage as desired concentrations. The efficacy of the MO was validated by semi-quantitative reverse transcriptase (RT) PCR.

Morphological analysis and quantification of lymphatic phenotype
----------------------------------------------------------------

Zebrafish embryos were anesthetized, plated and oriented laterally on a glass bottom dish at 4dpf. Image acquisition from zebrafish embryos was achieved using a Nikon confocal microscope and merged Z-stack images by MBF ImageJ program. The number of LECs in developing thoracic ducts of zebrafish embryos was individually counted from the trunk region spanning 7 somites, from somite boundary 8 or 9 to 15, on Z-stacked confocal images. Experiments were performed in triplicate. Quantification graphs were generated by PRISM program. Results were evaluated by two-tailed and/or unpaired Student's t test and each error bar represents the standard error of the mean (SEM).

RESULTS
=======

BMPRII/BMPR2 is the main type II receptor for BMP ligands, although BMP ligands can bind to ActRII and ActRIIB ([@b3-molcell-37-3-270-12]; [@b30-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]). In the zebrafish genome, two orthologs of human BMPR2, *bmpr2a* and *bmpr2b*, exist and are highly expressed in developing venous endothelial cells ([@b31-molcell-37-3-270-12]). To define the function of individual Bmpr2s during lymphatic development, we first attenuated the level of Bmpr2a and Bmpr2b activities by anti-sense morpholino oligonucleotide (MO)-mediated knock-down in *Tg(fli1a:nEGFP);Tg(kdrl:mCherry)* transgenic zebrafish embryos. This double transgenic line allows us to visualize individual lymphatic endothelial cells (LECs), therefore, allowing us to precisely quantify the number of developing LEC in the thoracic duct (TD) at 4dpf ([Fig. 1](#f1-molcell-37-3-270-12){ref-type="fig"}) ([@b17-molcell-37-3-270-12]; [@b33-molcell-37-3-270-12]). General morphology, heart beat rate, and development of blood vessels in embryos injected with a 3.6ng/embryo dose of MO were comparable to control MO-injected embryos (data not shown and [Figs. 1A](#f1-molcell-37-3-270-12){ref-type="fig"} and [1B](#f1-molcell-37-3-270-12){ref-type="fig"}). However, at 4dpf, the number of LECs in Bmp2a or Bmp2b-deficient embryos (1.45 ± 0.28 for *bmp2a* MO and 3.64 ± 1.11 for *bmp2a* MO) was substantially reduced compared to control embryos (9.17 ± 0.67) ([Figs. 1C](#f1-molcell-37-3-270-12){ref-type="fig"}--[1E](#f1-molcell-37-3-270-12){ref-type="fig"}), indicating that function of Bmpr2 is essential for lymphatic vessel development in zebrafish. Considering previous reports on anti-lymphangiogenic effects of BMP2 signaling in zebrafish ([@b8-molcell-37-3-270-12]), it is seemingly paradoxical that attenuation of Bmpr2 function adversely affects lymphatic development. However, it is important to take into consideration that Bmpr2 is not only required for BMP2 signaling, but is also essential for mediating pro-lymphangiogenic BMP9 signaling ([@b21-molcell-37-3-270-12]). In addition, it is possible that MO-mediated knock-down potentially affects venous endothelial cells, therefore, may indirectly influence LEC development. Regardless, our data illustrate Bmpr2 is essential for lymphatic development.

During BMP signal transduction, BMP type I receptors (BMPRIs, also known as Alks) are activated by BMP type II receptors upon ligand binding. While various TGF/BMP ligands may bind to BMP type II receptors, BMPRIs appear to retain certain ligand specificity or preference. Therefore, BMPRI most likely determines the down-stream effects and signaling outcomes of BMP signaling ([@b6-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]). While ALK2/ACVR1, ALK3/BMPR1A and ALK6/BMPR1B mediate the signal transduction of BMP subfamily ligands and induce phosphorylation of SMAD1, 5, 9, ALK1/ACVRL1 appears to relay signaling of both TGF and BMP subfamily ligands ([@b9-molcell-37-3-270-12]; [@b14-molcell-37-3-270-12]; [@b24-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]). To delineate the contribution of each BMP type I receptor in the formation of lymphatic vessel, we attenuated the level of Alk1, Alk2, Alk3, and Alk3b activities in zebrafish. Consistent with a previous report ([@b22-molcell-37-3-270-12]), the injections of MOs against *alk1* (7 ng/embryo), *alk2* (5.4 ng/embryo), *alk3* (14 ng/embryo), or *alk3b* (3.6 ng/embryo) at high concentrations cause gastrulation defects, and other morphological abnormalities such as cardiac edema (data not shown). Therefore, to bypass the earlier requirement of Alks, we titrated the concentration of MO to determine the dose which does not affect early development and heart formation. At lower concentration, MOs against each Alk receptor did not cause any discernible abnormalities in axis formation, cardiac morphogenesis, blood vessel development, or lymphatic vessel formation (3.6 ng/embryo for *alk1*, 2.7 ng/embryo for *alk2* MOs, 7 ng/embryo for *alk3*, and 1.8 ng/embryo for *alk3b*) (data not shown and [Fig. 2](#f2-molcell-37-3-270-12){ref-type="fig"}). Thus, a partial reduction of each Alk appears to have negligible effects on lymphatic vessel development ([Fig. 2](#f2-molcell-37-3-270-12){ref-type="fig"}). Since it is possible that BMPRIs have redundant roles during lymphatic development in zebrafish, we analyzed the lymphatic phenotype of embryos which were injected with a combination of MOs targeting two Alks. In case any two Alk receptors may function redundantly, injecting suboptimal doses of MO targeting both Alks together may create a synthetic phenotype, which cannot be observed when a single MO was injected with a suboptimal dose. When we injected *alk2* and *alk3* together at sub-optimal doses (1.4 ng/embryo for *alk2* MO and 3.6ng/embryo for *alk3*) ([Figs. 3A](#f3-molcell-37-3-270-12){ref-type="fig"}, [3B](#f3-molcell-37-3-270-12){ref-type="fig"}, and [3E](#f3-molcell-37-3-270-12){ref-type="fig"}), or *alk2* and *alk3b* together (1.4 ng/embryo for *alk2* MO and 0.9 ng/embryo for *alk3b*) ([Figs. 3A](#f3-molcell-37-3-270-12){ref-type="fig"}, [3C](#f3-molcell-37-3-270-12){ref-type="fig"}, and [3E](#f3-molcell-37-3-270-12){ref-type="fig"}), lymphatic vessels in the injected embryos were comparable to control embryos, suggesting that Alk2 does not have any redundant role with Alk3 or Alk3b in lymphatic development. In contrast, co-injection of *alk3* and *alk3b* MOs with a sup-optimal dosage caused a substantial loss of LECs in the developing TD at 4dpf ([Figs. 3A](#f3-molcell-37-3-270-12){ref-type="fig"}, [3D](#f3-molcell-37-3-270-12){ref-type="fig"}, and [3E](#f3-molcell-37-3-270-12){ref-type="fig"}), suggesting that Alk3 and Alk3b may redundantly regulate lymphatic development in zebrafish.

Upon activation, the BMP receptor complex induces phosphorylation of SMAD1, 5, 8 (9 in zebrafish), which is collectively known as R-SMAD (R-Smad in zebrafish). Phosphorylated R-SMADs translocate into the nucleus with Co-SMAD, and functions as a transcription factor to specific target genes ([@b15-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]). It is known that each SMAD has distinct roles dependent on the context of BMP signaling ([@b7-molcell-37-3-270-12]; [@b23-molcell-37-3-270-12]; [@b26-molcell-37-3-270-12]). For example, Smad1 and Smad5 appear to have an opposite effect in hematopoiesis of zebrafish ([@b23-molcell-37-3-270-12]). While the number of blood cells is increased in Smad1-deficient embryos, hematopoiesis is substantially decreased in Smad5-deficient embryos ([@b23-molcell-37-3-270-12]). Therefore, we speculate that each Smad might function differently in LECs of zebrafish. To examine this notion, we first designed splice-blocking MOs to inhibit the endogenous *smad* mRNA processing which allows us to bypass the early requirement of these genes (MO efficacy was validated by semi-quantitative RT-PCR in [Figs. 4A](#f4-molcell-37-3-270-12){ref-type="fig"} and [4B](#f4-molcell-37-3-270-12){ref-type="fig"}). Injection of splicing MO against each *smad* did not cause any morphological defects such as abnormalities in axis formation, cardiac function, or formation of blood vessels (data not shown). However, the number of LECs within the TD in *smad5* MO-injected embryos was drastically decreased (3.64 ± 0.70) compared to control embryos (8.04 ± 0.624). In contrast, we did not find any obvious decrease in the number of LECs in *smad1* or *smad9* MO-injected embryos ([Figs. 4C--4G](#f4-molcell-37-3-270-12){ref-type="fig"}). Therefore, Smad5 appears to be the most critical downstream mediator for BMP signaling in developing LECs in zebrafish.

DISCUSSION
==========

Our data demonstrate that BMP signaling is essential for developing lymphangiogenesis in zebrafish. Among BMP Type I receptors, combined function of Alk3 and Alk3b appear to be essential for lymphatic development, while Alk2 appears to be largely dispensable for this process. In addition, Smad5, but not Smad1 or Smad9, is required to mediate BMP signaling within LECs. Our findings are consistent with recent findings which suggest the importance of BMP signaling in LECs ([@b8-molcell-37-3-270-12]; [@b11-molcell-37-3-270-12]; [@b21-molcell-37-3-270-12]; [@b34-molcell-37-3-270-12]). For instance, the binding of BMP9 to ALK1 receptors inhibits lymphangiogenesis and regulates lymphatic valve formation and maturation of LECs ([@b21-molcell-37-3-270-12]; [@b34-molcell-37-3-270-12]). In addition, our recent data shows that the over-expression of Bmp2b at 48hpf in zebrafish decreases the number of LECs, illustrating the anti-lymphangiogenic activity of BMP2 signaling in lymphatic vessel formation ([@b8-molcell-37-3-270-12]). Therefore, as in the case of blood vessels ([@b16-molcell-37-3-270-12]; [@b20-molcell-37-3-270-12]; [@b25-molcell-37-3-270-12]; [@b31-molcell-37-3-270-12]), it appears that BMP signaling may modulate development and/or maintenance of lymphatic vessels in a context-dependent manner. Considering the complex regulation of BMP signaling in other systems ([@b5-molcell-37-3-270-12]; [@b6-molcell-37-3-270-12]; [@b11-molcell-37-3-270-12]; [@b14-molcell-37-3-270-12]; [@b24-molcell-37-3-270-12]), it is seemingly possible that distinct BMP ligands, of which distribution is spatiotemporally regulated, may exert pro- or anti-lymphangiogenic effects during development. Our analyses identify Smad5 as the most important downstream mediator of BMP signaling during lymphatic development. Considering that the majority of BMP signaling eventually converges at SMAD1, 5, 8/9, delineating how SMAD5 can distinguish activation by pro-lymphangiogenic BMP ligands (i.e. BMP9) and anti-lymphangiogenic BMP ligands (i.e. BMP2) may help us to better understand highly complex effects of BMP signaling in LECs.
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![Reduction in Bmpr2a and 2b activity causes loss of lymphatic endothelial cells in thoracic duct of zebrafish. Confocal images taken from the trunk region of 4dpf control (A, C), *bmpr2a* (B, D), and *bmpr2b* (C) MO-injected embryos in *Tg(fli1a:negfp); Tg(kdrl: mCherry)* double transgenic background. GFP^+^ mCherry^−^ cells are the lymphatic endothelial cells (LECs) within the thoracic duct (white arrows). (F) Quantification on the number of LECs in control, *bmpr2a*, and *bmpr2b* MO-injected embryos. LECs in the TD between 8^th^ and 15th somite were quantitated by confocal imaging analyses. Areas within the white rectangles in (A) and (B) are shown in higher magnification in (C) and (D). DA, dorsal aorta; CV, cardinal vein; ISV, intersegmental vessel. Scale bar is 50 μm.](molcell-37-3-270-12f1){#f1-molcell-37-3-270-12}

![A reduced level of individual Bmp type I receptors (BMPRI/Alks) does not cause lymphatic defects in zebrafish embryos. Confocal images of 4dpf control (A), *alk1* (B), *alk2* (C), *alk3* (D), and *alk3b* (E) MO-injected embryos in *Tg(fli1a:negfp); Tg(kdrl:mCherry)* double transgenic background. White arrows point LECs. (F) Quantification on the number of LECs in MO-injected embryos. DA, dorsal aorta; CV, cardinal vein. Scale bar is 50 μm.](molcell-37-3-270-12f2){#f2-molcell-37-3-270-12}

![Alk3 and Alk3b synergistically function to mediate Bmp signaling in lymphatic endothelial cells. Confocal images of 4dpf embryos injected with control (A), *alk2* and *alk3* (B), *alk2* and *alk3b* (C), and *alk3* and *alk3b* (D) MOs. Attenuating *alk3* and *alk3b* together drastically reduced the number of LECs in the TD. Arrows point LEC in TD. (E) Quantification on the number of LECs. DA, dorsal aorta; CV, cardinal vein. Scale bar is 50 μm.](molcell-37-3-270-12f3){#f3-molcell-37-3-270-12}

![Smad5 mediates the Bmp signaling in lymphatic endothelial cells in zebrafish. Validation of the MO efficacy by semi-quantitative RT-PCR. The transcripts of *smad5* (A) and *smad9* (B) were significantly decreased in embryos injected with MO against *smad5* (A) and *smad9* (B). Confocal images of 4dpf embryos injected with control (C), *smad1* (D), *smad5* (E), or *smad9* (F) MOs. Only *smad5* MO-injected embryos show discernible changes in the number of LECs. Arrows point LECs in the TD. (G) Quantification on the number of LECs. DA, dorsal aorta; CV, cardinal vein; ISV, interseg-mental vessel. Scale bar is 50 μm.](molcell-37-3-270-12f4){#f4-molcell-37-3-270-12}

###### 

Morpholinos (MO) used in this paper

  Zebrafish gene    Sequence                          MO type                References
  ----------------- --------------------------------- ---------------------- ----------------------------
                    5′-CCTCTTACCTCAGTTACAATTTATA-3′   Negative control       This study (gene tools)
  *bmpr2a*          5′-TCATTACGGAAACATACCTCTTAGC-3′   Splicing blocking      [@b31-molcell-37-3-270-12]
  *bmpr2b*          5′-AGTTGATTCTGACCTTGTTTGACCA-3′   Splicing blocking      [@b31-molcell-37-3-270-12]
  *ak1/acvrl1*      5′-CTGCGAGCATCACTGAAGCCTTC-3′     Translation blocking   [@b27-molcell-37-3-270-12]
  *alk2/acvr1l*     5′-GATTCATGTTTGTGTTCAATTTCCG-3′   Translation blocking   [@b2-molcell-37-3-270-12]
  *alk3/bmpr1aa*    5′-GACGCATTGTCAAATTGTCTTGTCG-3′   Translation blocking   [@b22-molcell-37-3-270-12]
  *alk3b/bmpr1ab*   5′-GTCGAGTTGTTGAACTGTATGGCTG-3′   Translation blocking   [@b22-molcell-37-3-270-12]
  *smad1*           5′-TAACAATTTAGCCACGCTCACCTGG-3′   Splicing blocking      [@b23-molcell-37-3-270-12]
  *smad5*           5′-ATCAGTGAAACCTACCTGGACTTTC-3′   Splicing blocking      This study
  *smad9*           5′-AGTCTGGACTGTCACCTCTTTGTGG-3′   Splicing blocking      This study
